SCHEMBL2188591

SCHEMBL2188591

CC(C)([C@H]1CCN(c2cnc(C(F)(F)F)nc2)C(=O)C1)S(=O)(=O)c1cccc(OC(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 2/20 0.41
CYP3A4 P08684 1/20 0.41
PIM1 P11309 1/20 0.40
AKR1C3 P42330 1/20 0.39
MCHR1 Q99705 1/20 0.38
KDM2B Q8NHM5 1/20 0.38
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
KCNH2 Q12809 1/20 0.37
SLC5A1 P13866 1/20 0.37
FGFR4 P22455 1/20 0.37
DHFR P00374 1/20 0.36
SLC40A1 Q9NP59 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
ROCK2 O75116 1/20 0.35
SCN9A Q15858 1/20 0.35
RORC P51449 1/20 0.35
HTR6 P50406 1/20 0.35
JAK2 O60674 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2189927 1.00 CACNA1B (0.41) CACNA1BCYP3A4PIM1AKR1C3MCHR1
SCHEMBL2191470 0.90 CACNA1B (0.42) CACNA1BCYP3A4PIM1AKR1C3MCHR1
SCHEMBL2190694 0.90 CACNA1B (0.42) CACNA1BCYP3A4PIM1AKR1C3MCHR1
SCHEMBL2188233 0.87 CYP3A4 (0.46) CACNA1BCYP3A4AKR1C3
SCHEMBL2190550 0.84 CACNA1B (0.44) CACNA1BCYP3A4PIM1AKR1C3MCHR1
SCHEMBL2189349 0.84 CACNA1B (0.44) CACNA1BCYP3A4PIM1AKR1C3MCHR1
SCHEMBL2188512 0.83 CACNA1B (0.43) CACNA1BCYP3A4PIM1AKR1C3MCHR1
SCHEMBL2187703 0.83 CACNA1B (0.43) CACNA1BCYP3A4PIM1AKR1C3MCHR1
SCHEMBL2188556 0.81 CACNA1B (0.40) CACNA1BCYP3A4PIM1AKR1C3MCHR1
SCHEMBL2186844 0.81 CACNA1B (0.40) CACNA1BCYP3A4PIM1AKR1C3MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CACNA1B 23/4885CYP3A4 939/4885PIM1 3329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.